Dipeptidyl-peptidase-4 inhibitors in type 2 diabetes and COVID-19: From a potential repurposed agent to a useful treatment option

Dipeptidyl-peptidase-4 inhibitors in type 2 diabetes and COVID-19: From a potential repurposed agent to a useful treatment option

Dipeptidyl-peptidase-4 inhibitors (DPP-4Is) are very commonly prescribed antidiabetic agents in the treatment of type 2 diabetes owing to its modest ability to reduce blood glucose without ensuing any hypoglycemia and weight gain. Many experts have advised continuing DPP-4Is in patient with type 2 d...

Full description

Bibliographic Details
Main Authors: Awadhesh Kumar Singh, Ritu Singh
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Journal of Diabetology
Subjects:
coronavirus disease 2019
dipeptidyl-peptidase-4 inhibitors
outcomes
severe acute respiratory syndrome coronavirus 2
type 2 diabetes
Online Access:http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2020;volume=11;issue=3;spage=131;epage=136;aulast=Singh

Internet

http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2020;volume=11;issue=3;spage=131;epage=136;aulast=Singh

Similar Items